BioPerfectus Technologies Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 581

Employees

  • Stock Symbol
  • 688399

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $2.71
  • (As of Friday Closing)

BioPerfectus Technologies General Information

Description

Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products and solutions involve: HPV & cervical cancer screening, Respiratory infection detection solution, Solutions for infectious diarrhea, STI detection solution for reproductive tract infections, Infectious disease testing, Maternal and child health, Disease prevention and control, Instrument, Scientific research services, and Other.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • BioPerfectus Technologies Industrial Park
  • Number 837 Yaocheng Avenue, Jiangsu Province
  • Taizhou, Jiangsu
  • China
+86 0523
Primary Industry
Diagnostic Equipment
Other Industries
Other Devices and Supplies
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • BioPerfectus Technologies Industrial Park
  • Number 837 Yaocheng Avenue, Jiangsu Province
  • Taizhou, Jiangsu
  • China
+86 0523

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioPerfectus Technologies Stock Performance

As of 20-Nov-2026, BioPerfectus Technologies’s stock price is $2.71. Its current market cap is $337M with 124M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.71 $2.93 $2.71 - $9.11 $337M 124M 1.94M -$0.03

BioPerfectus Technologies Financials Summary

As of 30-Sep-2026, BioPerfectus Technologies has a trailing 12-month revenue of $45M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 337,001 649,865 270,741 139,047
Revenue 45,037 47,147 48,723 56,987
EBITDA 104 3,592 4,299 (48,875)
Net Income (3,667) (5,712) (279) (52,836)
Total Assets 546,808 508,004 512,315 551,084
Total Debt 81,017 53,895 32,951 24,470
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioPerfectus Technologies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioPerfectus Technologies‘s full profile, request access.

Request a free trial

BioPerfectus Technologies Patents

BioPerfectus Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260317838-A1 Kit for detecting genital tract microorganism rapidly, synchronously and quantitatively, and microecological evaluation method thereof Pending 10-Apr-2025
US-20260022416-A1 Microsphere reagent for nucleic acid amplification Pending 30-Jul-2024
US-20250387104-A1 System for testing female reproductive health and diagnostic method Pending 11-Jul-2024
EP-4528278-A1 Sampling detection device Pending 30-Jun-2022
EP-4528278-A4 Sampling detection device Pending 30-Jun-2022 B01L3/5023
To view BioPerfectus Technologies’s complete patent history, request access »

BioPerfectus Technologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioPerfectus Technologies Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BioPerfectus Technologies‘s full profile, request access.

Request a free trial

BioPerfectus Technologies Investments (3)

BioPerfectus Technologies’s most recent deal was a Early Stage VC with Kadwise. The deal was made on 24-Jun-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Kadwise 24-Jun-2022 Early Stage VC Drug Discovery
Prophet Genomics 17-Jun-2022 Early Stage VC Diagnostic Equipment
Yuansong Biotechnology Corporate Drug Discovery
To view BioPerfectus Technologies’s complete investments history, request access »

BioPerfectus Technologies ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view BioPerfectus Technologies’s complete esg history, request access »

BioPerfectus Technologies FAQs

  • When was BioPerfectus Technologies founded?

    BioPerfectus Technologies was founded in 2010.

  • Where is BioPerfectus Technologies headquartered?

    BioPerfectus Technologies is headquartered in Taizhou, China.

  • What is the size of BioPerfectus Technologies?

    BioPerfectus Technologies has 581 total employees.

  • What industry is BioPerfectus Technologies in?

    BioPerfectus Technologies’s primary industry is Diagnostic Equipment.

  • Is BioPerfectus Technologies a private or public company?

    BioPerfectus Technologies is a Public company.

  • What is BioPerfectus Technologies’s stock symbol?

    The ticker symbol for BioPerfectus Technologies is 688399.

  • What is the current stock price of BioPerfectus Technologies?

    As of 20-Nov-2026 the stock price of BioPerfectus Technologies is $2.71.

  • What is the current market cap of BioPerfectus Technologies?

    The current market capitalization of BioPerfectus Technologies is $337M.

  • What is BioPerfectus Technologies’s current revenue?

    The trailing twelve month revenue for BioPerfectus Technologies is $45M.

  • What is BioPerfectus Technologies’s annual earnings per share (EPS)?

    BioPerfectus Technologies’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process